To examine whether MYCN expressing neuroblastoma cells exhibit similar sensitivity to cells harboring intrinsic PI3K pathway mutations we used NVP-BEZ235 to treat a range of adult cancer cell lines (PTEN or PIK3CA mutant, with varying expression levels of MYC [53–58]), together with pediatric cell lines (wild-type for PTEN and PIK3CA) but with varying expression levels of either MYC or MYCN (Figure 1F). The gene discussed is PIK3CA; the disease is neuroblastoma.